Breast cancer prevention drugs 'should be prescribed'
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Healthy women at high risk of breast cancer should be given drugs to help prevent them growing tumours, according to a group of international experts.
The controversial move would mirror the practice of prescribing cholesterol-reducing statins to patients in danger of developing heart disease.
Potential preventative drugs for breast cancer include tamoxifen and raloxifene, which target the female hormone oestrogen.
Both are approved in the US for breast cancer prevention but not in the UK.
Tamoxifen has side effects that may include an increased risk of womb cancer and blood clots.
The 12 experts, led by Professor Jack Cuzick, from Queen Mary, University of London, called for the change in a "consensus statement" published in the journal The Lancet Oncology.
They wrote: "To keep the devastating impact of breast cancer to a minimum, especially in the developed countries where prevalence is presently the highest, preventive therapy needs to be integrated into wider strategies of risk reduction, including avoidance of obesity and increase in physical activity."
Four large tamoxifen trials had shown that preventative treatment with the drug reduced the incidence of hormone-sensitive breast cancer by 43%, the authors pointed out.
Crucially, a reduced risk of new tumours had been observed for several years after active treatment ended.
Meg McArthur, from the charity Breakthrough Breast Cancer, said: "It is vital that we find effective ways to prevent breast cancer, especially in women with a high risk. However, as preventative therapy may have negative side effects it would not be appropriate for everyone.
"We welcome studies investigating the best treatments to be used for breast cancer prevention. It's also crucial to identify those at high risk who would benefit the most from this form of therapy."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments